HematologyNews.net

Hematology Xagena

Xagena Mappa
Medical Meeting
Pneumobase.it
Gastrobase.it

Search results for "Revlimid"

The IDMC ( Independent Data Monitoring Committee ) found a statistically significant improvement in time to disease progression in patients with multiple myeloma receiving Lenalidomide ( Revlimid ) pl ...


Initial clinical results from Pivotal Phase III Special Protocol Assessment ( SPA ) trials using Revlimid ( Lenalidomide ) as a new approach in the treatment of heavily pretreated patients with relaps ...


A multicenter Phase II trial, MDS-002, showed that Revlimid ( Lenalidomide ) is active in a larger group of patients with low and intermediate-1 risk myelodysplastic syndromes ( MDS ), who lack a dist ...


Researchers at the Mayo Clinic Cancer Center demonstrated that combination therapy with Lenalidomide ( Revlimid ) and Dexamethasone looks like a breakthrough treatment for multiple myeloma. The combi ...


Preliminary results from a large, randomized clinical trial for patients with newly diagnosed multiple myeloma, has shown that the use of a low dose of the steroid Dexamethasone ( Decadron ), in combi ...


Lenalidomide ( Revlimid ) is safe and well-tolerated for elderly patients with chronic lymphocytic leukaemia ( CLL ), a group without a well-defined frontline therapy for their disease, researchers fr ...


Lenalidomide ( Revlimid ) is safe and well-tolerated for elderly patients with chronic lymphocytic leukaemia ( CLL ), a group without a well-defined frontline therapy for their disease, researchers fr ...


High-dose Dexamethasone is a mainstay of therapy for multiple myeloma. However, a study published in the Lancet Oncology concludes that Lenalidomide ( Revlimid ) plus low-dose Dexamethasone is associa ...


A new three-drug combination has shown in a phase 1/2 clinical trial that it is a highly effective regimen in the treatment of patients newly diagnosed with multiple myeloma.Partial responses or bette ...


For patients with smoldering multiple myeloma, the standard of care is observation until symptoms develop. However, this approach does not identify high-risk patients who may benefit from early interv ...


The combination of lenalidomide ( Revlimid ) and Rituximab ( Rituxan ) has shown synergistic activity in chronic lymphocytic leukemia ( CLL ) preclinical models. In a CLL Research Consortium phase I ...


Lenalidomide ( Revlimid ) has been linked to second primary malignancies in myeloma. Researchers have aimed to pool and analyse available data to compare the incidence of second primary malignancies i ...


Up to 40% of elderly patients with untreated diffuse large B-cell lymphoma ( DLBCL ) given a regimen of Rituximab ( MabThera, Rituxan ), Cyclophosphamide ( Endoxan ), Doxorubicin ( Adriamycin ), Vincr ...


In 2013 American Society of Hematology ( ASH ) Annual Meeting data on several compounds in development for the treatment of multiple myeloma were presented. Alternating vs sequential regimens I ...


VMP and Rd are two of the most efficient and widely accepted regimens in the treatment of elderly newly diagnosed multiple myeloma patients. In order to further improve the outcome of elderly patients ...